Compare WS & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | WS | GENB |
|---|---|---|
| Founded | 1955 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2023 | 2026 |
| Metric | WS | GENB |
|---|---|---|
| Price | $37.52 | $9.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $27.00 |
| AVG Volume (30 Days) | 328.4K | ★ 868.3K |
| Earning Date | 12-16-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,443,800,000.00 | N/A |
| Revenue This Year | $11.55 | N/A |
| Revenue Next Year | $0.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.33 | N/A |
| 52 Week Low | $27.22 | $10.38 |
| 52 Week High | $49.17 | $22.67 |
| Indicator | WS | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 32.70 |
| Support Level | $36.04 | N/A |
| Resistance Level | $39.42 | $14.33 |
| Average True Range (ATR) | 2.38 | 1.20 |
| MACD | -0.48 | -0.34 |
| Stochastic Oscillator | 18.51 | 0.89 |
Worthington Steel Inc is a value-added metals processors with the ability to provide a diversified products and services that span a variety of end markets. It is a value-added processor of carbon flat-rolled steel and a producer of laser welded solutions and electrical steel laminations. It is one of the independent intermediate processors of carbon flat-rolled steel in the U.S. It occupy a niche in the steel industry by focusing on products requiring exact specifications. The company has one operating and reportable segment. It has presence in United States, Canada, Mexico, and Rest of world. The company has majority of sales from United States.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.